

Medical Affairs Internship

Position Summary

We are looking for an enthusiastic, creative, analytical, innovative, and strategic intern to join our Medical Affairs team. This position will provide support of project related activities for the Medical Affairs Department and reports to the head of Medical Affairs. This individual must be exceptionally organized, diligent, detail-oriented, flexible, team oriented, dynamic and adaptable to a fast-paced start-up environment.

This is a paid, 20-30 hours per week position with a hybrid schedule consisting of 3 days in-person and 2 days of working remotely in New Haven, CT. This position reports directly to the VP of Medical Affairs.

Principal Responsibilities

Key responsibilities of this role include, but are not limited to:

- Work with VP of Medical Affairs to manage Med Comm vendor on the execution of a publication plans, including abstract submissions, poster development and delivery, generation of manuscripts from initiation to final author approval
- Participate in the development of other medical communications activities, e.g. slide resource decks, scientific lexicon/medical narrative

Qualifications

- Intermediate to advance computer software skills with MS Office (Word, Excel, Outlook, PowerPoint)
- Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines
- Ability to work independently and as part of a team
- Strong interpersonal skills including verbal and written communication are essential in this collaborative work environment

Education

- High school or equivalent (Preferred)
- Currently enrolled full-time in an undergraduate program. Candidate must be pursuing a degree in healthcare, e.g. pre-med, pharmacology, nursing, etc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and for the treatment of prurigo nodularis. The Company reported statistically significant results from the Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF). Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).